Stratec SE (ETR:SBS)
Germany · Delayed Price · Currency is EUR | Market Cap | 237.04M -34.0% |
| Revenue (ttm) | 260.25M +1.8% |
| Net Income | 15.36M +21.8% |
| EPS | 1.26 +22.7% |
| Shares Out | 12.16M |
| PE Ratio | 15.43 |
| Forward PE | 14.03 |
| Dividend | 0.60 (3.08%) |
| Ex-Dividend Date | Jun 30, 2025 |
| Volume | 21,075 |
| Average Volume | 12,111 |
| Open | 19.34 |
| Previous Close | 19.28 |
| Day's Range | 18.94 - 19.58 |
| 52-Week Range | 18.94 - 33.10 |
| Beta | 0.72 |
| RSI | 37.75 |
| Earnings Date | Apr 28, 2026 |
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and integrating instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1... [Read more]
Financial Performance
In 2024, Stratec SE's revenue was 257.62 million, a decrease of -4.73% compared to the previous year's 270.41 million. Earnings were 16.02 million, an increase of 4.24%.
Financial StatementsNews
EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: STRATEC SE STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 17.02.2...